article thumbnail

How tech-driven hubs in specialty pharmacy can improve the patient experience

pharmaphorum

It’s estimated specialty medications account for 75% of the approximately 7,000 prescription drugs currently in development, and by 2022, more than 60% of the 600 drugs expected to gain FDA approval will be specialty medications. Navigating the cost of specialty medications.

article thumbnail

How to get Dupixent: Specialty pharmacy considerations

The Checkup by Singlecare

Dupixent (dupilumab) is an injectable prescription medication that’s approved by the Food and Drug Administration (FDA) to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps , prurigo nodularis, and eosinophilic esophagitis (EoE). “As What are specialty pharmacies? But there are some differences, too.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA approves omaveloxolone for treatment of Friedreich’s Ataxia

Hospital Pharmacy Europe

Following the FDA approval, the company has created the Reata Education, Access, and Care Helpline ( REACH ), an integrated specialty pharmacy and patient services program, designed to help eligible patients access prescribed Reata medicines.

FDA 97
article thumbnail

Relief for Amylyx as FDA clears controversial ALS drug Relyvrio

pharmaphorum

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug. The post Relief for Amylyx as FDA clears controversial ALS drug Relyvrio appeared first on.

FDA 98
article thumbnail

Roche takes on pricey rivals as FDA approves SMA drug

pharmaphorum

Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). The FDA approved Evrysdi for the treatment of spinal muscular atrophy (SMA) in adults and children two months of age and older.

FDA 59
article thumbnail

Insights on Quality in Rare Disease Medication Use

PQA

Only about five percent of rare diseases have treatments that are approved by the FDA, but the situation is improving. Ensuring the quality of medication use is critically important for rare disease patients, payers, clinicians, specialty pharmacies and everyone with a role in the care process.

article thumbnail

NASP 2022 Reveals a Pharmacy Landscape Shifting to Specialty

Omnicell

Kristen Dowd Director, Pharmacy Management Services, Omnicell If the 2022 NASP (National Association of Specialty Pharmacy) Annual Meeting and Expo is any indication, we are approaching a time when specialty pharmacy simply becomes pharmacy – when complex, high-touch biologics become nearly as ubiquitous as their broad-spectrum counterparts.